SG11201907324VA - Method for preventing or treating autism spectrum disorders by benzoic acid salt - Google Patents
Method for preventing or treating autism spectrum disorders by benzoic acid saltInfo
- Publication number
- SG11201907324VA SG11201907324VA SG11201907324VA SG11201907324VA SG11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA SG 11201907324V A SG11201907324V A SG 11201907324VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- preventing
- benzoic acid
- acid salt
- treating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229930188970 Justin Natural products 0.000 abstract 1
- 241001629697 Panicum turgidum Species 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001559 benzoic acids Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT oimiolo VIII °nolo VIII ioo no Elul° oimIE (10) International Publication Number WO 2018/160055 Al (51) International Patent Classification: A61K 31/192 (2006.01) A61P 25/28 (2006.01) A61K 31/196 (2006.01) A61P 43/00 (2006.01) A61P 25/18 (2006.01) (21) International Application Number: PCT/MY2018/000001 (22) International Filing Date: 04 January 2018 (04.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,749 03 March 2017 (03.03.2017) US (71) Applicants: EXCELSIOR PHARMATECH LABS [CN/CN]; 14F-7, No. 3, Park St., Nangang Dist., Taipei, Taiwan 11503 (CN). YING-TUNG, Lee [MY/MY]; 8, Jalan Bukit Permai 1/3, Taman Bukit Permai, Bandar Sun- gai Long, Selangor, 43000 (MY). (72) Inventor; and (71) Applicant: HSIEN-YUAN, Lane [CN/CN]; 12F-5, No.360, Jianxing Rd., North Dist., Taichung, 404 (TW). (72) Inventor: PIN-CHEN, Yang; No. 100, Tzyou 1st Road, Kaohsiung, 807 (TW). (74) Agent: JUSTIN, Anandan Santiago; Nanyang IP Sdn Bhd, 30-3, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur, 59000 (MY). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) as to non prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) Published: with international search report (Art. 21(3)) O O (54) Title: METHOD FOR PREVENTING OR TREATING AUTISM SPECTRUM DISORDERS BY BENZOIC ACID SALT 00 (57) : The present disclosure provides a method for preventing or treating an autism spectrum disorder in a subject in need O thereof. The method includes administering to the subject a composition containing a therapeutically effective amount of a benzoic acid salt and a pharmaceutically acceptable excipient thereof. Also provided is a composition for use in preventing or treating an autism C spectrum disorder in a subject in need thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762466749P | 2017-03-03 | 2017-03-03 | |
PCT/MY2018/000001 WO2018160055A1 (en) | 2017-03-03 | 2018-01-04 | Method for preventing or treating autism spectrum disorders by benzoic acid salt |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907324VA true SG11201907324VA (en) | 2019-09-27 |
Family
ID=63370205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907324VA SG11201907324VA (en) | 2017-03-03 | 2018-01-04 | Method for preventing or treating autism spectrum disorders by benzoic acid salt |
Country Status (10)
Country | Link |
---|---|
US (1) | US10987327B2 (en) |
JP (1) | JP6940631B2 (en) |
KR (1) | KR102272280B1 (en) |
AU (1) | AU2018227291B2 (en) |
CA (1) | CA3054679C (en) |
DE (1) | DE212018000171U1 (en) |
MY (1) | MY198069A (en) |
SG (1) | SG11201907324VA (en) |
TW (1) | TWI681771B (en) |
WO (1) | WO2018160055A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081875A (en) * | 2021-11-25 | 2022-02-25 | 南京医科大学 | New application of sodium benzoate |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001041707A2 (en) | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
WO2009018368A1 (en) * | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
TWI455712B (en) * | 2010-01-19 | 2014-10-11 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | |
US20150265559A1 (en) | 2014-03-19 | 2015-09-24 | Kaohsiung Chang Gung Memorial Hospital of the C.G.M.F. | Benzoates for use in treating dementia |
AU2014386718B8 (en) | 2014-03-24 | 2017-12-07 | China Medical University | Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment |
-
2018
- 2018-01-04 JP JP2019569654A patent/JP6940631B2/en active Active
- 2018-01-04 CA CA3054679A patent/CA3054679C/en active Active
- 2018-01-04 AU AU2018227291A patent/AU2018227291B2/en active Active
- 2018-01-04 DE DE212018000171.5U patent/DE212018000171U1/en active Active
- 2018-01-04 KR KR1020197026362A patent/KR102272280B1/en active IP Right Grant
- 2018-01-04 MY MYPI2019004687A patent/MY198069A/en unknown
- 2018-01-04 WO PCT/MY2018/000001 patent/WO2018160055A1/en active Application Filing
- 2018-01-04 US US16/488,532 patent/US10987327B2/en active Active
- 2018-01-04 TW TW107100336A patent/TWI681771B/en not_active IP Right Cessation
- 2018-01-04 SG SG11201907324VA patent/SG11201907324VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201832763A (en) | 2018-09-16 |
JP2020511530A (en) | 2020-04-16 |
MY198069A (en) | 2023-07-31 |
WO2018160055A1 (en) | 2018-09-07 |
US20200061005A1 (en) | 2020-02-27 |
CA3054679A1 (en) | 2018-09-07 |
TWI681771B (en) | 2020-01-11 |
KR20190117601A (en) | 2019-10-16 |
US10987327B2 (en) | 2021-04-27 |
WO2018160055A8 (en) | 2019-11-14 |
CA3054679C (en) | 2021-09-07 |
KR102272280B1 (en) | 2021-07-06 |
AU2018227291A1 (en) | 2019-09-12 |
AU2018227291B2 (en) | 2021-02-11 |
JP6940631B2 (en) | 2021-09-29 |
DE212018000171U1 (en) | 2019-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
SG11201901070YA (en) | Formulations for oral administration of active agents | |
SG11201810618QA (en) | Depot formulations | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea |